BR112023018844A2 - Composições e métodos para geração de células t gama-delta de células-tronco pluripotentes induzidas - Google Patents
Composições e métodos para geração de células t gama-delta de células-tronco pluripotentes induzidasInfo
- Publication number
- BR112023018844A2 BR112023018844A2 BR112023018844A BR112023018844A BR112023018844A2 BR 112023018844 A2 BR112023018844 A2 BR 112023018844A2 BR 112023018844 A BR112023018844 A BR 112023018844A BR 112023018844 A BR112023018844 A BR 112023018844A BR 112023018844 A2 BR112023018844 A2 BR 112023018844A2
- Authority
- BR
- Brazil
- Prior art keywords
- cells
- methods
- pluripotent stem
- induced pluripotent
- delta
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 3
- 210000004263 induced pluripotent stem cell Anatomy 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 210000004027 cell Anatomy 0.000 abstract 1
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/804—Blood cells [leukemia, lymphoma]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/145—Thrombopoietin [TPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/165—Vascular endothelial growth factor [VEGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2303—Interleukin-3 (IL-3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/415—Wnt; Frizzeled
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases (EC 2.)
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/90—Polysaccharides
- C12N2501/91—Heparin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Abstract
composições e métodos para geração de células t gama-delta de células-tronco pluripotentes induzidas. a presente invenção refere-se a métodos para gerar células t ?d a partir de células-tronco pluripotentes induzidas. também são fornecidas ipscs geneticamente modificadas, células t ?d, células t car-?d e métodos de uso das mesmas.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163171646P | 2021-04-07 | 2021-04-07 | |
US202163279837P | 2021-11-16 | 2021-11-16 | |
PCT/US2022/022793 WO2022216514A1 (en) | 2021-04-07 | 2022-03-31 | Compositions and methods for generating gamma-delta t cells from induced pluripotent stem cells |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112023018844A2 true BR112023018844A2 (pt) | 2023-10-10 |
Family
ID=81648414
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112023018844A BR112023018844A2 (pt) | 2021-04-07 | 2022-03-31 | Composições e métodos para geração de células t gama-delta de células-tronco pluripotentes induzidas |
Country Status (9)
Country | Link |
---|---|
US (1) | US20220333073A1 (pt) |
EP (1) | EP4320227A1 (pt) |
KR (1) | KR20230170703A (pt) |
AU (1) | AU2022252997A1 (pt) |
BR (1) | BR112023018844A2 (pt) |
CA (1) | CA3214045A1 (pt) |
IL (1) | IL307358A (pt) |
TW (1) | TW202305113A (pt) |
WO (1) | WO2022216514A1 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023164440A1 (en) | 2022-02-22 | 2023-08-31 | Juno Therapeutics, Inc. | Proteinase 3 (pr3) chimeric autoantibody receptor t cells and related methods and uses |
WO2023240147A1 (en) | 2022-06-08 | 2023-12-14 | Century Therapeutics, Inc. | Genetically engineered cells expressing cd16 variants and nkg2d and uses thereof |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6344321B1 (en) | 1990-06-11 | 2002-02-05 | Gilead Sciences, Inc. | Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met |
ES2162823T5 (es) | 1992-08-21 | 2010-08-09 | Vrije Universiteit Brussel | Inmunoglobulinas desprovistas de cadenas ligeras. |
GB9710807D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
US6140081A (en) | 1998-10-16 | 2000-10-31 | The Scripps Research Institute | Zinc finger binding domains for GNN |
US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
JP2002060786A (ja) | 2000-08-23 | 2002-02-26 | Kao Corp | 硬質表面用殺菌防汚剤 |
EP1421177A4 (en) | 2001-08-20 | 2006-06-07 | Scripps Research Inst | ZINC FINGER FASTENING DOMAINS FOR CNN |
US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
US7972854B2 (en) | 2004-02-05 | 2011-07-05 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
US8574179B2 (en) | 2004-09-17 | 2013-11-05 | Stp Swiss Therapeutic Products Ag | Enhanced biomechanical stimulation device |
KR101516833B1 (ko) | 2007-03-23 | 2015-05-07 | 위스콘신 얼럼나이 리서어치 화운데이션 | 체세포 재프로그래밍 |
KR101648019B1 (ko) | 2008-06-04 | 2016-08-16 | 셀룰러 다이내믹스 인터내셔널, 인코포레이티드 | 비-바이러스 접근법을 사용한 iPS 세포의 생산 방법 |
JP2012506702A (ja) | 2008-10-24 | 2012-03-22 | ウイスコンシン アラムニ リサーチ ファンデーション | 非ウイルス性再プログラムによる多能性幹細胞 |
JP5816100B2 (ja) | 2009-02-27 | 2015-11-18 | セルラー ダイナミクス インターナショナル, インコーポレイテッド | 多能性細胞の分化 |
PL3222617T3 (pl) | 2009-03-19 | 2023-01-02 | The Johns Hopkins University | Związki do kierunkowania w psma i ich zastosowania |
PL2510096T5 (pl) | 2009-12-10 | 2018-06-29 | Regents Of The University Of Minnesota | Modyfikacja DNA zależna od efektora TAL |
US9206394B2 (en) | 2010-02-03 | 2015-12-08 | The University Of Tokyo | Method for reconstructing immune function using pluripotent stem cells |
JP5936218B2 (ja) | 2010-08-04 | 2016-06-22 | セルラー ダイナミクス インターナショナル, インコーポレイテッド | 不死化b細胞のリプログラミング |
JP6005666B2 (ja) | 2011-02-08 | 2016-10-12 | セルラー ダイナミクス インターナショナル, インコーポレイテッド | プログラミングによる造血前駆細胞の生産 |
DE102012006356A1 (de) | 2012-03-28 | 2013-10-02 | Audi Ag | Kraftfahrzeug, umfassend mehrere aktive oder passive Sicherheitsvorrichtungen |
US9932607B2 (en) | 2013-11-15 | 2018-04-03 | The Board Of Trustees Of The Leland Stanford Junior University | Site-specific integration of transgenes into human cells |
WO2015143029A1 (en) | 2014-03-18 | 2015-09-24 | The Johns Hopkins University | Psma-based molecular-genetic reporter system |
JP6715482B2 (ja) | 2014-07-18 | 2020-07-01 | 国立大学法人京都大学 | 多能性幹細胞から免疫細胞療法用t細胞を誘導する方法 |
CA3002157A1 (en) | 2015-10-20 | 2017-04-27 | FUJIFILM Cellular Dynamics, Inc. | Methods for directed differentiation of pluripotent stem cells to immune cells |
EP3444334B9 (en) | 2016-04-15 | 2023-12-20 | Kyoto University | Method for inducing antigen specific cd8 positive t cells |
CN109952309A (zh) | 2016-08-26 | 2019-06-28 | 贝勒医学院 | 用于细胞治疗的组成型活性细胞因子受体 |
JP7215994B2 (ja) | 2016-09-06 | 2023-01-31 | ザ チルドレンズ メディカル センター コーポレーション | 人工多能性幹細胞由来の免疫細胞 |
KR102397771B1 (ko) | 2016-09-23 | 2022-05-13 | 프레드 헛친슨 켄서 리서치 센터 | 부 조직적합성(h) 항원 ha-1에 대해서 특이적인 tcr 및 이의 용도 |
US20200263139A1 (en) | 2016-10-05 | 2020-08-20 | FUJIFILM Cellular Dynamics, Inc. | Methods for directed differentiation of pluripotent stem cells to hla homozygous immune cells |
JP7136454B2 (ja) * | 2017-01-20 | 2022-09-13 | 国立大学法人京都大学 | CD8α+β+細胞傷害性T細胞の製造方法 |
US20200017837A1 (en) * | 2017-02-03 | 2020-01-16 | National University Corporation Kobe University | Method For Producing Induced Pluripotent Stem Cells |
MX2019012017A (es) | 2017-04-07 | 2020-02-12 | Juno Therapeutics Inc | Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados. |
JP7181219B2 (ja) | 2017-04-18 | 2022-11-30 | フジフィルム セルラー ダイナミクス,インコーポレイテッド | 抗原特異的免疫エフェクター細胞 |
CN111432823A (zh) | 2017-07-25 | 2020-07-17 | 得克萨斯大学体系董事会 | 增强的嵌合抗原受体及其用途 |
KR20230007557A (ko) | 2017-09-22 | 2023-01-12 | 카이트 파마 인코포레이티드 | 키메라 폴리펩티드 및 그의 용도 |
WO2019070856A1 (en) | 2017-10-03 | 2019-04-11 | Precision Biosciences, Inc. | MODIFIED EPIDERMAL GROWTH FACTOR RECEPTOR PEPTIDES FOR USE IN GENETICALLY MODIFIED CELLS |
CN111556892A (zh) * | 2017-12-08 | 2020-08-18 | 菲特治疗公司 | 使用增强的iPSC衍生的效应细胞的免疫疗法 |
AU2019302207A1 (en) * | 2018-07-13 | 2021-03-04 | Kyoto University | Method for producing γδ T cells |
KR20210061397A (ko) | 2018-09-19 | 2021-05-27 | 후지필름 셀룰러 다이내믹스, 인코포레이티드 | 키메라 항원 수용체-변형된 면역 세포의 활성화 및 확장을 위한 단백질 l |
CN113383071A (zh) * | 2018-11-01 | 2021-09-10 | 亘喜生物科技(上海)有限公司 | 用于t细胞工程化的组合物和方法 |
-
2022
- 2022-03-31 BR BR112023018844A patent/BR112023018844A2/pt unknown
- 2022-03-31 KR KR1020237038118A patent/KR20230170703A/ko unknown
- 2022-03-31 WO PCT/US2022/022793 patent/WO2022216514A1/en active Application Filing
- 2022-03-31 IL IL307358A patent/IL307358A/en unknown
- 2022-03-31 EP EP22723243.6A patent/EP4320227A1/en active Pending
- 2022-03-31 CA CA3214045A patent/CA3214045A1/en active Pending
- 2022-03-31 AU AU2022252997A patent/AU2022252997A1/en active Pending
- 2022-04-04 US US17/657,798 patent/US20220333073A1/en active Pending
- 2022-04-07 TW TW111113220A patent/TW202305113A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CA3214045A1 (en) | 2022-10-13 |
KR20230170703A (ko) | 2023-12-19 |
WO2022216514A9 (en) | 2023-12-21 |
US20220333073A1 (en) | 2022-10-20 |
AU2022252997A1 (en) | 2023-09-28 |
TW202305113A (zh) | 2023-02-01 |
IL307358A (en) | 2023-11-01 |
EP4320227A1 (en) | 2024-02-14 |
WO2022216514A1 (en) | 2022-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112023018844A2 (pt) | Composições e métodos para geração de células t gama-delta de células-tronco pluripotentes induzidas | |
MA45747A (fr) | Génération de cellules bêta fonctionnelles à partir de progéniteurs endocrines dérivés de cellules souhes pluripotentes humaines | |
CL2021002147A1 (es) | Células asesinas naturales (nk) modificadas para inmunoterapia | |
BR112021021725A2 (pt) | Proteínas policlonais recombinantes e métodos de uso das mesmas | |
EA201892680A1 (ru) | Композиция для укрепления волос и способ укрепления волос | |
BR112013026501A2 (pt) | métodos para preparar um oócito, de fertilização in vitro, e para aumentar a capacidade de geração de atp de um oócito, oócito, e, composição | |
BR112012026379A2 (pt) | métodos para gerar proteína endogenamente marcada | |
BRPI1011934A8 (pt) | Composição | |
AR051527A1 (es) | Planta transformada que expresa una dextranosucrasa y sintetiza un almidon modificado | |
BR112022001207A2 (pt) | Método de obtenção de mitocôndrias de células e mitocôndrias obtidas | |
BR112018003031A2 (pt) | formulações clínicas | |
CO2021001064A2 (es) | Método para la producción de las células t gamma delta | |
MX2019002956A (es) | Generador de casos de prueba integrado en editor de flujo de trabajo para integracion de datos. | |
BR112019015754A2 (pt) | métodos e micro-organismos para fabricar 2,3-butanodiol e derivados deste a partir de carbonos c1 | |
BR112021014645A2 (pt) | Método de edição de genes | |
WO2021257730A3 (en) | Cells modified by a cas12i polypeptide | |
BR112018015312A2 (pt) | cepa fúngica isolada, cultura biologicamente pura, composição inoculante, kit, uso de uma cepa, e, método para aumentar quantidade/concentração de fosfato solúvel em um meio que contém fosfato insolúvel | |
BR112021023554A2 (pt) | Composições e métodos para cultura de células vegetais | |
MX2019011933A (es) | Composiciones cosmeticas que contienen sistema enzimatico. | |
CO2021013699A2 (es) | Líneas celulares productoras diseñadas genéticamente y métodos de elaboración y uso de las mismas | |
BR112022002491A2 (pt) | Formulações de cbd e usos das mesmas | |
CO2023010208A2 (es) | Proteínas de unión a psma y usos de estas | |
BR112021026326A2 (pt) | Sacarose fosforilase engenheirada, composição, sequência de polinucleotídeo, vetor de expressão, célula hospedeira, e, método para produzir uma sacarose fosforilase engenheirada | |
WO2016087314A3 (en) | Genetically modified higher plants with increased photosynthesis and/or biomass production, methods and uses thereof | |
MX2021002702A (es) | Metodos para expandir celulas t del receptor de antigeno quimerico especificas de antigenos, composiciones y usos relacionados con las mismas. |